Back to search results
NCT06572683

Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder

Enrolling by Invitation
NAAges 21–75InterventionalTreatment
University of California, Los Angeles
~84 participants
Updated 2025-09-22 on ClinicalTrials.gov
What's tested:Transcranial Magnetic Stimulation

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Repeatability of the Resonant Frequency measure
Measured over 1 week per subject (Three RF measurements will happen within 1 week)
+3 more outcomes measured

Conditions

MDD
Depression

Explore related trials

Unipolar Depression

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Joe Gibbs · STUDY_CHAIR · University of California, Los Angeles

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All subjects must be between 21-75 years of age.
Must have confirmed diagnosis of severe \*Major Depressive Disorder (single or recurrent episode) as confirmed by the Mini-International Neuropsychiatric Interview (MINI) or/and a score of 17 or above on the Hamilton Depression Rating Scale (HAMD).
Failure to respond to a minimum of 2 trials of antidepressant medication.
Failure to respond from at least two different agent classes.
Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count).
Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration.
Subjects are willing and able to adhere to the treatment schedule and required study visits.
TMS treatment is clinically-approved only for those suffering from Major Depressive Disorder as their primary diagnosis.

Exclusion

Are mentally or legally incapacitated, unable to give informed consent
Have an infection or poor skin condition over the scalp where the device will be positioned.
Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure.
Diagnosis of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode.
Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system.
Presence of an implanted magnetic-sensitive medical device present in the body scan, located less than or equal to 30 centimeters from the transcranial magnetic stimulation magnetic coil or other implanted metal items, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents. (Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with transcranial magnetic stimulation and MRI.)
Current diagnosis of substance use disorder.

What this trial measures

  • Repeatability of the Resonant Frequency measure1 week per subject (Three RF measurements will happen within 1 week)

    Resonant Frequency (RF) of brain oscillations will be measured three times for each participant. Each time, all unique frequencies will be assigned a ranking corresponding to the degree of elicited network activity. We will then compute pairwise Spearman's correlation coefficients (R) between individual rankings obtained at time 1 (T1) vs time 2 (T2), T1 vs Time 3 (T3), and T2 vs T3. We expect that all R-values will be above R = 0.4. This will be single-subject level analysis.

  • Changes in Electroencephalograms (EEG) functional connectivityTen days for each subject (2 sessions (RFmax/RFmin) separated by one week).

    Electroencephalograms functional connectivity (EEG-FC) will be measured after rTMS stimulation 1) at the maximal and 2) at the minimal RF (RFmax, RFmin, respectively), as derived from the ranking using Outcome Measure 1. We will compare changes in EEG-FC after RFmax to changes in EEG-FC after RFmin. This will be a group-level analysis.

  • Spatial maps of source-localized EEG connectivityTen days for each subject (2 sessions (RFmax/RFmin) separated by one week)

    We will quantitatively compare the spatial extend of source-localized connectivity elicited by RFmax vs. RFmix stimulation. Binary statistical connectivity maps will be compared for size and percentage of overlap between the two conditions.

  • Percent overlap between spatial maps of source-localized EEG connectivity and fMRI-based MDD-rTMS responsive network1 week per subject.

    Similar to Outcome measure 3, but instead of comparing the spatial extend of EEG connectivity between RFmax vs. RFmin, this analysis will quantify the similarity to an MDD-rTMS responsive network derived from functional MRI data (Siddiqi et al. 2020).